Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161525 | 0.94 | CNR1 (0.36) | CNR1CRBNMEN1KMT2APDK1 | |
| SCHEMBL31161368 | 0.91 | MEN1 (0.39) | CRBNMEN1KMT2APDK1PDK2 | |
| SCHEMBL31161548 | 0.88 | CNR1 (0.41) | CNR1CRBNMEN1KMT2APDK1 | |
| SCHEMBL23123648 | 0.87 | CNR1 (0.43) | CNR1CRBNMEN1KMT2APDK1 | |
| SCHEMBL31161308 | 0.87 | CNR1 (0.43) | CNR1CRBNMEN1KMT2APDK1 | |
| Trifluoroacetic Acid SCHEMBL30009088 | 0.84 | CNR1 (0.40) | CNR1CRBNMEN1KMT2APDK1 | |
| SCHEMBL31161762 | 0.83 | ACACB (0.36) | CRBNMEN1KMT2APDK1PDK2 | |
| SCHEMBL31161355 | 0.83 | CNR1 (0.35) | CNR1CRBNMEN1KMT2APDK1 | |
| SCHEMBL27123605 | 0.82 | SOS1 (0.43) | CNR1CRBNMEN1KMT2APDK1 | |
| SCHEMBL31677220 | 0.81 | MEN1 (0.41) | CRBNMEN1KMT2APDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | CNR1 350/4885CRBN 91/4885MEN1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.